OPKO Health (NASDAQ:OPK) Raised to Hold at StockNews.com

StockNews.com upgraded shares of OPKO Health (NASDAQ:OPK) from a sell rating to a hold rating in a research report sent to investors on Monday.

Several other equities analysts also recently weighed in on the stock. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday.

OPKO Health Trading Up 0.6 %

Shares of OPK stock opened at $1.75 on Monday. The stock has a market capitalization of $1.19 billion, a P/E ratio of -9.21 and a beta of 1.63. OPKO Health has a 12-month low of $0.86 and a 12-month high of $1.84. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The firm’s 50 day moving average is $1.55 and its 200 day moving average is $1.55.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Research analysts expect that OPKO Health will post -0.25 earnings per share for the current year.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $1.59 per share, for a total transaction of $198,750.00. Following the acquisition, the chief executive officer now directly owns 212,536,477 shares of the company’s stock, valued at $337,932,998.43. This represents a 0.06 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have bought 1,389,971 shares of company stock worth $2,124,442 over the last quarter. Insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in OPKO Health by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 8,064 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after acquiring an additional 8,396 shares in the last quarter. FMR LLC increased its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares in the last quarter. Comerica Bank increased its holdings in shares of OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 16,369 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of OPKO Health by 4.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock valued at $670,000 after acquiring an additional 18,571 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.